ArticleBJOG : an international journal of obstetrics and gynaecology2010
High fever following postpartum administration of sublingual misoprostol.
Article in BJOG : an international journal of obstetrics and gynaecology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 45 citations in OpenAlex.
- Effectiveness and safety of misoprostol distributed to antenatal women to prevent postpartum haemorrhage after child-births: a stepped-wedge cluster-randomized trial.BMC pregnancy and childbirth · 2015Trial
- Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in Uganda: a double-blind randomized non-inferiority trial.PLoS medicine · 2014Trial
- Hyperpyrexia with hemodynamic instability after sublingual misoprostol: case report and literature review.AJOG global reports · 2026Article
- Article
- Misoprostol-Induced Fever and Unnecessary Antibiotic Prescribing: A Retrospective Study.Infectious diseases and therapy · 2023Article
- High fever after sublingual administration of misoprostol for treatment of post-partum haemorrhage: a hospital-based, prospective observational study in Argentina.Tropical medicine & international health : TM & IH · 2020Observational
- Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach.Einstein (Sao Paulo, Brazil) · 2020Observational
- Prophylactic uterotonics in the prevention of primary postpartum haemorrhage for unplanned out-of-hospital births: a literature review.British paramedic journal · 2019Article
- Sublingual misoprostol and hyperpyrexia: case report with temperature curve.BMC research notes · 2017Article
- Misoprostol Induced Convulsion-A Rare Side Effect of Misoprostol.Journal of clinical and diagnostic research : JCDR · 2017Article
- Association between infection and fever in terminations of pregnancy using misoprostol: a retrospective cohort study.BMC pregnancy and childbirth · 2017Article
- Dose and side effects of sublingual misoprostol for treatment of postpartum hemorrhage: what difference do they make?BMC pregnancy and childbirth · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore what triggers an elevated body temperature of > or =40.0 degrees C in some women given misoprostol, a prostaglandin E1 analogue, for postpartum haemorrhage (PPH).
designPost hoc analysis.
settingOne tertiary-level hospital in Quito, Ecuador. POPULATION: A cohort of 58 women with a fever of above 40 degrees C following treatment with sublingual misoprostol (800 micrograms) for PPH.
methodsSide effects were documented for 163 Ecuadorian women given sublingual misoprostol to treat their PPH. Women's body temperatures were measured, and if they had a fever of > or =40.0 degrees C, measurements were taken hourly until the fever subsided. Temperature trends were analysed, and the possible physiological mechanisms by which postpartum misoprostol produces a high fever were explored.
main outcome measuresThe onset, duration, peak temperatures, and treatments administered for cases with a high fever.
resultsFifty-eight of 163 women (35.6%) treated with misoprostol experienced a fever of > or =40.0 degrees C. High fevers followed a predictable pattern, often preceded by moderate/severe shivering within 20 minutes of treatment. Body temperatures peaked 1-2 hours post-treatment, and gradually declined over 3 hours. Fevers were transient and did not lead to any hospitalisation. Baseline characteristics were comparable among women who did and did not develop a high fever, except for known previous PPH and time to placental expulsion.
conclusionsAn unexpectedly high rate of elevated body temperature of > or =40.0 degrees C was documented in Ecuador following sublingually administered misoprostol. It is unclear why temperatures > or =40.0 degrees C occurred with a greater frequency in Ecuador than in other study populations using similar treatment regimens for PPH. Pharmacogenetic studies may shed further light on variations in individuals' responses to misoprostol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.